Quarterly report pursuant to Section 13 or 15(d)

Sponsored Research and License Agreements and Government Contract (Details)

v3.21.2
Sponsored Research and License Agreements and Government Contract (Details) - USD ($)
1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended
Feb. 28, 2021
Jan. 31, 2021
Feb. 29, 2020
Jan. 31, 2020
Dec. 31, 2019
Oct. 31, 2019
Jan. 31, 2019
Oct. 31, 2018
Jun. 30, 2021
Mar. 31, 2021
Jun. 30, 2020
Mar. 31, 2020
Jun. 30, 2021
Jun. 30, 2020
Dec. 31, 2019
Dec. 31, 2020
Collaborations                                
Upfront payment received                         $ 125,000,000.0      
Accretion expense                 $ 1,000,000.0       1,100,000      
Accounts receivable                 17,372,000       17,372,000     $ 15,973,000
License agreement with unrelated third party                                
Collaborations                                
Proceeds from License Fees Received $ 4,000,000.0                              
One-time fee received from license rights granted $ 4,000,000.0                              
Revenue recognized                   $ 4,000,000            
Specified Development Events                                
Collaborations                                
Contingent payments                         312,500,000      
Specified Regulatory Events                                
Collaborations                                
Contingent payments                         303,200,000      
Specified Product Launch Events                                
Collaborations                                
Contingent payments                         816,000,000.0      
Development and regulatory milestones by non-CNS disease products                                
Collaborations                                
Contingent payments                         330,000,000.0      
Development and regulatory milestones by non-CNS disease products | Milestone payments on a product-by-product basis                                
Collaborations                                
Contingent payments                         100,000,000.0      
Development and regulatory milestones by CNS disease products                                
Collaborations                                
Contingent payments                         255,000,000.0      
Development and regulatory milestones by CNS disease products | Milestone payments on a product-by-product basis                                
Collaborations                                
Contingent payments                         150,000,000.0      
Maximum                                
Collaborations                                
Contingent payments                         1,400,000,000      
Grifols                                
Collaborations                                
Upfront payment received             $ 30,000,000.0                  
Contingent payments                         277,500,000      
Revenue, cumulative catch-up       $ 25,000,000.0                        
Deferred revenue                 1,200,000       1,200,000     1,600,000
Revenue, remaining performance obligation                               $ 5,000,000.0
Grifols | Licensed Rights                                
Collaborations                                
Revenue recognized                       $ 39,900,000        
Grifols | Research Services                                
Collaborations                                
Revenue recognized                     $ 396,000          
Grifols | Commercial Milestones                                
Collaborations                                
Contingent payments             $ 297,500,000                  
Revenue recognized                   1,000,000.0            
Grifols | Upon EMA approval of fostamatinib for treatment of chronic ITP                                
Collaborations                                
Revenue, cumulative catch-up       $ 20,000,000.0                        
Kissei                                
Collaborations                                
Upfront payment received               $ 33,000,000.0                
Contingent payments               $ 147,000,000.0                
Revenue recognized                           $ 0    
Deferred revenue                 1,400,000       1,400,000      
Revenue, remaining performance obligation                 33,000,000.0       33,000,000.0      
Lilly                                
Collaborations                                
Deferred revenue                 3,200,000       3,200,000      
fostamatinib                                
Collaborations                                
Government contract   $ 16,500,000                            
Revenue recognized                 5,500,000       8,500,000      
Accounts receivable                 4,000,000.0       4,000,000.0      
Remaining amount of government award expected to be received in succeeding periods                         8,000,000.0      
fostamatinib | Grifols                                
Collaborations                                
Collaborative payment received     $ 20,000,000.0                          
Markup percentage         30.00%                      
fostamatinib | Grifols | Upon EMA approval of fostamatinib for treatment of chronic ITP                                
Collaborations                                
Contingent payments     17,500,000                          
fostamatinib | Grifols | Creditable advance royalty payment                                
Collaborations                                
Collaborative payment received     $ 2,500,000                          
fostamatinib | Grifols | Maximum                                
Collaborations                                
Royalty payment as a percentage of net sales                             30.00%  
fostamatinib | Medison Pharma | Financing arrangement                                
Collaborations                                
Upfront payment received           $ 5,000,000.0                    
Accrued interest                 337,000   $ 0   337,000 0    
Financing liability with accreted interest expense                 5,500,000       $ 5,500,000      
fostamatinib | Medison Pharma | Commercial and license agreements                                
Collaborations                                
Upfront payment received           $ 5,000,000.0                    
R552                                
Collaborations                                
Company's percentage of development costs                         20.00%      
Financing component liability                 57,900,000       $ 57,900,000      
Financing liability interest accretion discount rate                         6.40%      
Financing liability with accreted interest expense                 59,000,000.0       $ 59,000,000.0      
Revenue, remaining performance obligation                 67,100,000       67,100,000      
R552 | Maximum                                
Collaborations                                
Funding commitment                 65,000,000.0       65,000,000.0      
Non-CNS penetrant IP                                
Collaborations                                
Revenue recognized                   60,400,000            
Non-CNS penetrant IP | Licensed Rights                                
Collaborations                                
Revenue, remaining performance obligation                   $ 6,700,000            
CNS penetrant IP                                
Collaborations                                
Revenue recognized                 3,300,000       3,500,000      
Research and development services | Grifols                                
Collaborations                                
Revenue recognized                 $ 381,000       $ 381,000      
Research Services | Grifols                                
Collaborations                                
Revenue recognized                           $ 3,600,000